期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Multicenter Clinical Study for Evaluation of Efficacy and Safety of Transdermal Fentanyl Matrix Patch in Treatment of Moderate to Severe Cancer Pain in 474 Chinese Cancer Patients 被引量:6
1
作者 Yu-lin Zhu Guo-hong Song +17 位作者 Duan-qi Liu Xi Zhang Kui-feng Liu Ai-hua Zang Ying Cheng Guo-chun Cao Jun Liang Xue-zhen Ma Xin Ding Bin Wang Wei-lian Li Zuo-wei Hu Gang Feng Jiang-jin Huang Xiao Zheng Shun-chang Jiao Rong Wu Jun Ren 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2011年第4期317-322,共6页
Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have b... Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods: A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 ?g/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results: After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63?1.26 to 2.03?1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001). Conclusion: The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life. 展开更多
关键词 transdermal fentanyl matrix patch (TDF) Cancer pain EFFICACY Safety Quality of life
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部